Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 3/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | TK2 | O00142 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | BLM | P54132 | 1/20 | 0.58 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | TYMS | P04818 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5872494 | 1.00 | TK1 (0.60) | TK1LMNASMN1; SMN2TK2CYP1A2 | |
| SCHEMBL17384092 | 0.88 | TK1 (0.55) | TK1LMNASMN1; SMN2TK2CYP1A2 | |
| SCHEMBL5872460 | 0.85 | TYMS (0.76) | TK1LMNASMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL5982466 | 0.85 | TYMS (0.76) | TK1LMNASMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL13273335 | 0.85 | TYMS (0.76) | TK1LMNASMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL5982470 | 0.85 | TYMS (0.76) | TK1LMNASMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL19777590 | 0.85 | TYMS (0.76) | TK1LMNASMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL5872464 | 0.85 | TYMS (0.76) | TK1LMNASMN1; SMN2CYP1A2CYP3A4 | |
| Doxribtimine SCHEMBL645753 | 0.83 | TK1 (0.64) | TK1LMNASMN1; SMN2TK2 | |
| SCHEMBL13413043 | 0.82 | TK1 (0.59) | TK1LMNASMN1; SMN2TK2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7057027-B2 | Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines | ISIS PHARMACEUTICALS, INC. (US) | 2006-06-06 | — | — | US | disclosed |
| US-6962783-B2 | Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines | ISIS PHARMACEUTICALS, INC. (US) | 2005-11-08 | — | — | US | disclosed |
| US-6875593-B2 | Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines | ISIS PHARMACEUTICALS, INC. (US) | 2005-04-05 | — | — | US | disclosed |
| US-20040265802-A9 | ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES | FROEHLER BRIAN (US) | 2004-12-30 | — | — | US | disclosed |
| US-20040220395-A1 | Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines | ISIS PHARMACEUTICALS, INC. | 2004-11-04 | — | — | US | disclosed |
| US-20030170680-A1 | Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines | FROEHLER BRIAN (US) | 2003-09-11 | — | — | US | disclosed |
| US-20030096980-A1 | Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines | ISIS PHARMACEUTICALS, INC. | 2003-05-22 | — | — | US | disclosed |
| EP-1256589-A2 | Oligomers containing modified pyrimidines | ISIS PHARMACEUTICALS, INC. (US) | 2002-11-13 | — | — | EP | disclosed |
| EP-0637965-B1 | ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES | ISIS PHARMACEUTICALS INC (US) | 2002-10-16 | — | — | EP | disclosed |
| US-6380368-B1 | GENETIC ENGINEERING | ISIS PHARMACEUTICALS, INC. | 2002-04-30 | — | — | US | disclosed |
| US-5830653-A | ABILITY TO INHIBIT GENE EXPRESSION | GILEAD SCIENCES, INC. (US) | 1998-11-03 | — | — | US | disclosed |
| US-5645985-A | USED FOR DIAGNOSIS TO DETECT VIRUSES OR DISEASED CONDITIONS | GILEAD SCIENCES, INC. (US) | 1997-07-08 | — | — | US | disclosed |
| EP-0637965-A4 | ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES. | GILEAD SCIENCES INC (US) | 1996-01-24 | — | — | EP | disclosed |
| EP-0637965-A1 | ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES | GILEAD SCIENCES, INC. (US) | 1995-02-15 | — | — | EP | disclosed |
| WO-1993010820-A1 | ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES | GILEAD SCIENCES, INC. (US) | 1993-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030170680-A1 | Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines | NUDT1, DHX15, DDX5 | TK1 43/4885LMNA 1678/4885SMN1; SMN2 907/4885 |
| US-20040265802-A9 | ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES | NUDT1, DHX15, DDX5 | TK1 43/4885LMNA 1678/4885SMN1; SMN2 907/4885 |
| US-20040220395-A1 | Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines | NUDT1, DHX15, DDX5 | TK1 43/4885LMNA 1678/4885SMN1; SMN2 907/4885 |
| US-20030096980-A1 | Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines | NUDT1, DHX15, DDX5 | TK1 43/4885LMNA 1678/4885SMN1; SMN2 907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.